20 March 2024
20 March 2024
The FDA's decision was based on the positive outcomes of the EFFISAYIL 2 clinical trial.
The approval for the treatment was granted based on data from the PAINT and PICTURE studies.
As AstraZeneca looks to move past chemotherapy and radiotherapy, it will enter a market firmly controlled by Novartis.
The new initiative aims to spur innovation and mobilisation of sectors to drive women’s health research.
In addition to drug discovery deals, NVIDIA also announced partnerships with J&J MedTech and GE Healthcare for genAI in MedTech.
TB is the leading determiner of death in patients with HIV, yet while new drug research is underway, funding and accessible treatments remain distant.
This marks a new era in medicines distribution, which might be concerning for pharmacies such as CVS and Boots.
Asieris presented positive Phase III results at the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting in San Diego, US.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
